GeoVax Labs Reports Third Quarter 2026 Financial Results
GeoVax Labs reported a third-quarter 2026 net loss of $4.2 million, or $10.56 per share, versus a $6.3 million loss a year earlier, with no revenue. Research and development expenses fell 44.1% year over year, reflecting the end of a BARDA contract and lower costs for GEO-CM04S1 and Gedeptin, partly offset by higher GEO-MVA manufacturing costs. The company discontinued its GEO-CM04S1 COVID-19 vaccine candidate to focus on GEO-MVA and Gedeptin. GeoVax had $2.2 million in cash at September 30, plus a $1 million revolving loan, which it expects to fund operations only through December 2026, raising substantial doubt about its ability to continue as a going concern.
AI summary, not financial advice